IceCure Medical 将来の成長

Future 基準チェック /56

IceCure Medicalは、62.7%と57.9%でそれぞれ年率62.7%で利益と収益が成長すると予測される一方、EPSはgrowで64.2%年率。

主要情報

62.7%

収益成長率

64.2%

EPS成長率

Medical Equipment 収益成長	17.1%
収益成長率	57.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	26 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqCM:ICCM - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	33	-2	-11	N/A	1
12/31/2025	8	-13	-13	N/A	3
12/31/2024	3	-14	-15	N/A	2
9/30/2024	4	-14	-11	-11	N/A
6/30/2024	3	-14	-11	-11	N/A
3/31/2024	3	-14	-13	-12	N/A
12/31/2023	3	-15	-13	-13	N/A
9/30/2023	3	-16	-15	-14	N/A
6/30/2023	3	-16	-15	-14	N/A
3/31/2023	3	-16	-15	-14	N/A
12/31/2022	3	-17	-15	-14	N/A
9/30/2022	4	-16	-17	-16	N/A
6/30/2022	4	-15	-17	-16	N/A
3/31/2022	3	-13	-14	-14	N/A
12/31/2021	4	-10	-13	-13	N/A
9/30/2021	4	-8	-9	-8	N/A
6/30/2021	4	-6	-7	-6	N/A
3/31/2021	4	-4	-5	-5	N/A
12/31/2020	4	-4	-4	-4	N/A
9/30/2020	3	-4	-2	-2	N/A
6/30/2020	3	-4	-1	0	N/A
3/31/2020	2	-4	-1	-1	N/A
12/31/2019	2	-5	-2	-2	N/A
9/30/2019	1	-5	N/A	N/A	N/A
6/30/2019	1	-4	-4	-4	N/A
3/31/2019	1	-4	-4	-4	N/A
12/31/2018	1	-4	-3	-3	N/A
9/30/2018	1	-3	N/A	N/A	N/A
6/30/2018	1	-3	N/A	-3	N/A
3/31/2018	1	-3	N/A	-3	N/A
12/31/2017	1	-3	N/A	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-3	N/A	-3	N/A
12/31/2016	1	-3	N/A	-3	N/A
9/30/2016	1	-3	N/A	-3	N/A
6/30/2016	1	-4	N/A	-4	N/A
3/31/2016	1	-4	N/A	-3	N/A
12/31/2015	1	-4	N/A	-3	N/A
9/30/2015	1	-4	N/A	-3	N/A
6/30/2015	1	-4	N/A	-3	N/A
3/31/2015	1	-4	N/A	-3	N/A
12/31/2014	1	-5	N/A	-3	N/A
9/30/2014	1	-5	N/A	-4	N/A
6/30/2014	1	-5	N/A	-4	N/A
3/31/2014	0	-5	N/A	-3	N/A
12/31/2013	0	-5	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ICCMは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: ICCM今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ICCM今後 3 年以内に収益を上げることが予想されます。

収益対市場: ICCMの収益 ( 57.9% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ICCMの収益 ( 57.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ICCMの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

IceCure Medical 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2026

Price target increased by 14% to US$3.33

Forecast to breakeven in 2026

Price target decreased by 15% to US$3.41

Price target decreased by 14% to US$3.96

Price target decreased to US$4.58

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

IceCure Medical Ltd to Report Q3, 2024 Results on Nov 26, 2024

IceCure Medical Ltd has filed a Follow-on Equity Offering.

IceCure Medical Ltd. Announces Study Publishes in British Journal of Radiology Demonstrates IceCure's ProSense is Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of Lung, Bone, and Soft Tissues

IceCure Medical Ltd. Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

U.S. Patent and Trademark Office Grants Notice of Allowance for Additional Patent on IceCure Medical Ltd.'s Novel Cryogenic Pump Technology

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

IceCure Medical Ltd Announces the Publication of an Independent Study of Patients Who Chose Cryoablation for the Treatment of Early Breast Cancer in Non-Surgical Patients

IceCure Medical Ltd to Report Q2, 2024 Results on Aug 20, 2024

IceCure Medical Ltd. Announces Positive Data from the Largest Multi-Institutional Study of Its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials

Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Invest In Growth?

New minor risk - Share price stability

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical Ltd. Announces the Publication of an Independent Study Evaluating its Cryoablation System ProSense

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes

New minor risk - Shareholder dilution

FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

IceCure Medical Ltd to Report Q1, 2024 Results on May 28, 2024

IceCure Medical Ltd, Annual General Meeting, May 20, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Icecure Submits FDA Regulatory Filing for New Xsense™ Cryoablation System with Cryoprobes

IceCure Medical Ltd to Report Fiscal Year 2023 Results on Apr 03, 2024

Price target increased by 14% to US$3.33

IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study

IceCure Medical Ltd. Announces Results from an Independent Study

Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study

IceCure Medical Ltd has filed a Follow-on Equity Offering in the amount of $9.7 million.

IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Forecast to breakeven in 2026

IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients

IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense

We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer

IceCure Medical Ltd to Report Q3, 2023 Results on Nov 15, 2023

Icecure Medical Ltd. Announces Provides Update on Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's Prosense Cryoablation System

New major risk - Revenue and earnings growth

IceCure Medical Ltd. Receives FDA Response to De Novo Classification Request for Breast Cancer

Price target decreased by 15% to US$3.41

Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil

Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil

Second quarter 2023 earnings: EPS misses analyst expectations

IceCure Medical Ltd to Report Q2, 2023 Results on Aug 14, 2023

Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Deliver On Growth Plans?

Health Canada Approves Icecure Medical's Minimally Invasive Prosense Cryoablation System

New major risk - Financial position

New major risk - Revenue and earnings growth

IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023

Insufficient new directors

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 14% to US$3.96

IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump

IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems

IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022

Price target decreased to US$4.58

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

Price target decreased to US$4.58

IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

IceCure gains 19% on seeking FDA nod for cancer treatment

IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense®

Second quarter 2022 earnings released

IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022

IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

IceCure files application for approval of ProSense in Canada for tumors